Abbott Agrees to Settle U.S. Overpayment Claims
This article is for subscribers only.
Abbott Laboratories and two other drugmakers agreed to pay $421.2 million to settle claims they overcharged the U.S. for medicines, the Justice Department said.
Boehringer Ingelheim GmbH’s Roxane Inc. will pay $280 million, Abbott will pay $126.5 million and B. Braun Melsungen AG will pay $14.7 million. Boehringer and B. Braun are closely held. The settlements resolve civil claims that the companies inflated the average wholesale prices for drugs reported to the federal health programs Medicare and Medicaid.